You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020177026
Dec 20203709
Jan 20215408
Feb 202132010
Mar 202166014
Apr 202170020
May 202124013
Jun 2021009
Jul 20210015
Aug 20210014
Sep 20210012
Oct 202146026
Nov 202151018
Dec 202142015
Jan 20223804
Feb 20226509
Mar 202258012
Apr 2022132011
May 202250013
Jun 2022110014
Jul 20227006
Aug 202294016
Sep 20226209
Oct 20225006
Nov 20224005
Dec 20226805
Jan 20238208
Feb 20237404
Mar 20238806
Apr 202348013
May 20235803
Jun 20236007
Jul 202386016
Aug 202387012
Sep 202354011
Oct 202346011
Nov 20234208
Dec 202370012
Jan 20242408
Feb 20244409
Mar 202474015
Apr 202446021
May 202454011
Jun 202464010
Jul 2024132013
Aug 20246606
Sep 202482021
Oct 202464014
Nov 202460022
Dec 202444020
Jan 2025106026
Feb 202510012
Mar 20250021
Apr 20250015
May 20250015
Jun 20250018
Total31010707